Cargando…

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD. Mice received chow diet and normal water (CDNW)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Divya P., Caffrey, Rebecca, Marioneaux, Jonathon, Santhekadur, Prasanna K., Bhat, Madhavi, Alonso, Cristina, Koduru, Srinivas V., Philip, Binu, Jain, Mukul R., Giri, Suresh R., Bedossa, Pierre, Sanyal, Arun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283326/ https://www.ncbi.nlm.nih.gov/pubmed/32518275 http://dx.doi.org/10.1038/s41598-020-66458-z

Ejemplares similares

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis
por: Zhang, Yanmei, et al.
Publicado: (2021)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
por: Cazanave, Sophie, et al.
Publicado: (2017)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
por: Cazanave, Sophie, et al.
Publicado: (2020)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Genistein Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγ in a Rat Model
por: Susutlertpanya, Warinda, et al.
Publicado: (2015)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis
por: Ramirez, Teresa, et al.
Publicado: (2012)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
por: Suresh, Diwakar, et al.
Publicado: (2023)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Serum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Ramachandran, Prasanna, et al.
Publicado: (2022)

Herpetrione, a New Type of PPARα Ligand as a Therapeutic Strategy Against Nonalcoholic Steatohepatitis
por: Linghu, Lang, et al.
Publicado: (2023)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis: Current Scenario and Future Prospects
por: Jadeja, Ravirajsinh, et al.
Publicado: (2014)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis
por: Roy, Akash, et al.
Publicado: (2023)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
por: Huang, Peng, et al.
Publicado: (2018)

Genistein Modulated Lipid Metabolism, Hepatic PPARγ, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH)
por: Pummoung, Sudaporn, et al.
Publicado: (2020)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4jos6li8psoo8r4d3oj0bnuikj